Integrated Filing — IndAS



General information about company

Scrip Code 506235
NSE Symbol ALEMBICLTD
MSEI Symbol NOTLISTED
ISIN INE426A01027
Name of company Alembic Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 11-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 31-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 11-08-2026   15:30:00
End date and time of board meeting 11-08-2026   16:00:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 4,874.24 4,874.24
Other income 596.30 596.30
Total income 5,470.54 5,470.54
2 Expenses
(a) Cost of materials consumed 492.86 492.86
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (51.49) (51.49)
(d) Employee benefit expense 1,046.10 1,046.10
(e) Finance costs 60.46 60.46
(f) Depreciation, depletion and amortisation expense 347.68 347.68
(f) Other Expenses
1 Cost of Construction 862.13 862.13
2 Other Expenses 978.91 978.91
Total other expenses 1,841.04 1,841.04
Total expenses 3,736.65 3,736.65
3 Total profit before exceptional items and tax 1,733.89 1,733.89
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,733.89 1,733.89
6 Tax expense
7 Current tax 192.92 192.92
8 Deferred tax (28.69) (28.69)
9 Total tax expenses 164.23 164.23
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,569.66 1,569.66
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 4,919.01 4,919.01
16 Total profit (loss) for period 6,488.67 6,488.67
17 Other comprehensive income net of taxes 6,371.38 6,371.38
18 Total Comprehensive Income for the period 12,860.05 12,860.05
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 6,488.67 6,488.67
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 6,371.38 6,371.38
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 5,135.64 5,135.64
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.53 2.53
Diluted earnings (loss) per share from continuing operations 2.53 2.53
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.53 2.53
Diluted earnings (loss) per share from continuing and discontinued operations 2.53 2.53
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. 3. The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full finanacial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025. 4.Figures rounded off to the nearest decimal.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Active Pharmaceutical Ingredients Business 1,171.30 1,171.30
2 Real Estate Business 3,702.94 3,702.94
Total Segment Revenue 4,874.24 4,874.24
Less: Inter segment revenue 0.00 0.00
Revenue from operations 4,874.24 4,874.24
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Active Pharmaceutical Ingredients Business 166.46 166.46
2 Real Estate Business 1,397.64 1,397.64
Total Profit before tax 1,564.10 1,564.10
i. Finance cost 60.46 60.46
ii. Other Unallocable Expenditure net off Unallocable income (230.25) (230.25)
Profit before tax 1,733.89 1,733.89
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Active Pharmaceutical Ingredients Business 18,228.27 18,228.27
2 Real Estate Business 52,873.11 52,873.11
Total Segment Asset 71,101.38 71,101.38
Un-allocable Assets 2,00,855.55 2,00,855.55
Net Segment Asset 2,71,956.93 2,71,956.93
4 Segment Liabilities
Segment Liabilities
1 Active Pharmaceutical Ingredients Business 3,576.58 3,576.58
2 Real Estate Business 7,765.20 7,765.20
Total Segment Liabilities 11,341.78 11,341.78
Un-allocable Liabilities 3,246.54 3,246.54
Net Segment Liabilities 14,588.32 14,588.32
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss 7,048.17 7,048.17
Total Amount of items that will not be reclassified to profit and loss 7,048.17
2 Income tax relating to items that will not be reclassified to profit or loss 752.42 752.42
3 Amount of items that will be reclassified to profit and loss
1 Amount of items that will be reclassified to profit and loss 89.61 89.61
Total Amount of items that will be reclassified to profit and loss 89.61
4 Income tax relating to items that will be reclassified to profit or loss 13.98 13.98
5 Total Other comprehensive income 6,371.38 6,371.38